TegoScience Inc (191420) Fair Value & Analysis
Healthcare · KR · Market cap 65.2B KRW
Fair value as of: Jul 7, 2026
From 3 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 28,148 KRW to 3,785 KRW (−86.6%) since Jun 24, 2026. Share price −12.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 6,510 KRW – 18,970 KRW · fair‑value band 2,498 KRW – 4,731 KRW · the 7,340 KRW price screens above the 3,785 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TegoScience Inc (191420) currently trades at 7,340 KRW, while our model-based Fair Value estimate is 3,785 KRW — implying the stock looks roughly 48.4% overvalued today. We read business quality at 26/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, TegoScience Inc generated revenue of 8.4B KRW at a net margin of 16.0%. Revenue grew 4.1% year over year. Net debt stands at 3.4B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 2,498 KRW (bear case) to 4,731 KRW (bull case); at 7,340 KRW, the current price sits above that range. The share trades about 62% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -8% fair-value upside — at -48%, 191420 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TegoScience Inc reported revenue of 5.9B KRW in FY2025 versus 8.3B KRW in FY2021, a compound −8.0%/yr. Reported net income was −7.0B KRW in FY2025.
Is 191420 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 119,500 KRW | 62,226 KRW | -48% |
| NatureCell Co 007390 | 30,800 KRW | 901.89 KRW | -97% |
| Oscotec Inc 039200 | 37,000 KRW | 34,117 KRW | -8% |
| DongKook Pharmaceutical Co 086450 | 20,100 KRW | 32,962 KRW | +64% |
| Kolon Life Science Inc 102940 | 43,600 KRW | 37,195 KRW | -15% |
| BINEX Co 053030 | 6,900 KRW | 27,024 KRW | +292% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 22,700 KRW | 49,475 KRW | +118% |
| Vivozon Pharmaceutical Co 082800 | 2,765 KRW | 2,928 KRW | +6% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
| Prestige Biologics Co 334970 | 1,907 KRW | 564.18 KRW | -70% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TegoScience Inc (191420) undervalued?
What is the fair value of 191420?
What is the quality score of 191420?
What is the revenue of TegoScience Inc (191420)?
What is the net profit margin of 191420?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.